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Antihypertensive Treatment With b-Blockade in Patients With
Asymptomatic Aortic Stenosis and Association With Cardiovascular
Events
Casper N. Bang, MD, PhD; Anders M. Greve, MD, PhD; Anne B. Rossebø, MD; Simon Ray, MD, PhD; Kenneth Egstrup, MD, DMSc;
Kurt Boman, MD, PhD; Christoph Nienaber, MD; Peter M. Okin, MD; Richard B. Devereux, MD; Kristian Wachtell, MD, PhD, DMSc
Background-—Patients with aortic stenosis (AS) often have concomitant hypertension. Antihypertensive treatment with a b-blocker
(Bbl) is frequently avoided because of fear of depression of left ventricular function. However, it remains unclear whether
antihypertensive treatment with a Bbl is associated with increased risk of cardiovascular events in patients with asymptomatic mild
to moderate AS.
Methods and Results-—We did a post hoc analysis of 1873 asymptomatic patients with mild to moderate AS and preserved left
ventricular ejection fraction in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study. Propensity-matched Cox regression
and competing risk analyses were used to assess risk ratios for all-cause mortality, sudden cardiac death, and cardiovascular
death. A total of 932 (50%) patients received Bbl at baseline. During a median follow-up of 4.30.9 years, 545 underwent aortic
valve replacement, and 205 died; of those, 101 were cardiovascular deaths, including 40 sudden cardiovascular deaths. In adjusted
analyses, Bbl use was associated with lower risk of all-cause mortality (hazard ratio 0.5, 95% conﬁdence interval 0.3-0.7, P<0.001),
cardiovascular death (hazard ratio 0.4, 95% conﬁdence interval 0.2-0.7, P<0.001), and sudden cardiac death (hazard ratio 0.2, 95%
conﬁdence interval 0.1-0.6, P=0.004). This was conﬁrmed in competing risk analyses (all P<0.004). No interaction was detected
with AS severity (all P>0.1).
Conclusions-—In post hoc analyses Bbl therapy did not increase the risk of all-cause mortality, sudden cardiac death, or
cardiovascular death in patients with asymptomatic mild to moderate AS. A prospective study may be warranted to determine if Bbl
therapy is in fact beneﬁcial.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00092677. ( J Am Heart Assoc. 2017;6:
e006709. DOI: 10.1161/JAHA.117.006709.)
Key Words: aortic valve stenosis • arrhythmia (heart rhythm disorders) • atrial ﬁbrillation • b-blocker • high blood pressure
• hypertension
A ortic stenosis (AS) represents a condition of leftventricular (LV) pressure overload resulting in neuroen-
docrine activation, including a heightened b-adrenergic state,
reduced myocyte protein synthesis, and extracellular matrix
degradation comparable to heart failure.1 This cardiovascular-
valvular coupling is important because there is little evidence
of the ability of cardiotropic drugs to improve outcomes in
patients with AS.2 Moreover, hypertension is a frequent
ﬁnding in patients with AS, and we have recently shown the
importance of lowering blood pressure on reducing adverse
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cardiovascular outcome in patients with asymptomatic AS.3
Nevertheless, the current guidelines do not specify whether
antihypertensive treatment should differ from that used in
patients without AS.
b-Blockers (Bbls) are interesting in this regard, as they
might reduce oxygen consumption and lower blood pressure
to improve survival in AS patients.4 However, Bbls may also
pose a danger of reduced inotropy in AS, and evidence for the
safety and efﬁcacy of Bbl use in AS is scarce. This study was
therefore undertaken to investigate the association of Bbls
with risk of cardiovascular and all-cause mortality as well as of
sudden cardiac death during long-term follow-up in the SEAS
(Simvastatin and Ezetimibe in Aortic Stenosis) study, which is,
to date, the largest cohort of patients with asymptomatic mild
to moderate AS.
Methods
The SEAS study was a randomized, multicenter, double-blind,
placebo-controlled study investigating whether intensive lipid
lowering with simvastatin plus ezetimibe in combination
versus placebo in 1873 patients (45-85 years of age) with
asymptomatic AS (deﬁned as echocardiographic aortic valve
thickening accompanied by Doppler-measured aortic peak
ﬂow velocity between 2.5 and 4.0 m/s, normal LV systolic
function, and absence of symptoms according to independent
local investigators based on patient interviews) could
decrease AS progression and associated risk of cardiovascu-
lar morbidity and mortality. Patients were excluded if they had
received a diagnosis or had symptoms of coronary artery
disease, heart failure, peripheral arterial disease, cerebrovas-
cular disease, or diabetes mellitus or if they had any other
condition requiring lipid-lowering therapy. The primary out-
come, design, and baseline characteristics of the SEAS study
have been published.5,6 In this report post hoc analyses were
used to investigate the association between baseline use of
Bbls (as reported by the study investigators at enrollment into
the study) and subsequent mortality and cardiovascular
outcomes. The SEAS study and its substudies comply with
the Declaration of Helsinki; locally appointed ethics commit-
tees have approved the research protocol, and informed
consent has been obtained. The SEAS trial is registered at
http://ClinicalTrials.gov, unique identiﬁer NCT00092677.
Echocardiography
The echocardiographic study protocol, reading procedures,
and reproducibility have been published.7 Brieﬂy, all echocar-
diograms were read blinded at the SEAS Echocardiographic
Core Laboratory, Haukeland University Hospital, Bergen,
Norway. Aortic valve area indexed by body surface area was
calculated by applying the continuity equation.8,9 LV dimen-
sions and wall thicknesses were measured on 2-dimensional
images according to American Society of Echocardiography
guidelines using an anatomically validated formula. The aortic
valve area and LV mass, both indexed by body surface area,
and the LV ejection fraction were determined by standard 2D-
echocardiography.10,11
End Points and Adjudication
All end points were evaluated according to a predeﬁned
endpoint protocol by an independent end-point classiﬁcation
committee blinded to the randomization as outlined by the
SEAS steering committee.6 The primary outcome in this post
hoc substudy was all-cause mortality. Secondary end points
were cardiovascular and sudden cardiac death. Exploratory
analyses were performed on other end points including major
cardiovascular events, a composite of ﬁrst myocardial infarc-
tion, nonhemorrhagic stroke, heart failure, aortic valve
replacement (AVR), or cardiovascular death and the individual
components of major cardiovascular events as well as
coronary artery bypass grafting (CABG) and percutaneous
coronary intervention.
Statistical Analysis
SAS statistical software package version 9.4 for PC (SAS
Institute Inc, Cary, NC) was used for statistical analysis.
Continuous variables are presented as meanstandard
deviation and categorical data as number and percentages.
Variables not normally distributed are presented as medians
with interquartile ranges. Differences in categorical variables
were evaluated by chi-squared tests, and thode in contin-
uous variables by the Student t test or Wilcoxon test as
appropriate. Changes in echocardiographic parameters,
heart rate, and systolic blood pressure according to Bbl
therapy were examined by t test on changes in values from
baseline to the last recorded. To assess the independent
effect of baseline Bbl use on end points, a propensity score
for baseline Bbl therapy was quantiﬁed by multivariate
Clinical Perspective
What Is New?
• b-Blockade seems safe in patients with mild to moderate
aortic stenosis.
What Are the Clinical Implications?
• b-Blockers may be used if patients develop arrhythmias and
may be the drug of choice if patients with aortic stenosis
develop hypertension.
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logistic regression analysis. Covariates for the propensity
model were selected by examining the combination of
pertinent predictor variables that resulted in the optimal
prediction of baseline Bbl use (see Data S1 and Table S1 for
predictor variables). To avoid excluding patients who missed
1 or more baseline variables included in the propensity
score, missing variables were imputed according to age- and
sex-speciﬁc strata. Using the Greedy matching macro
(http://www.mayo.edu/research/departments-divisions/de
partment-health-sciences-research/division-biomedical-statis
tics-informatics/software/locally-written-sas-macros), we
matched each case to 1 control on the basis of the
propensity score. Kaplan-Meier and Cox regression analyses
on the matched data set were performed to approximate
the independent effect of baseline Bbl therapy. Competing
risk analyses were performed as described by Fine and Gray
using all-cause mortality as a competing event to evaluate if
the difference in survival altered the risk of nonexclusive
end points.12 Comprehensive sensitivity analyses were
performed by (1) tests of interaction between Bbl therapy
and baseline variables presumed to have an inﬂuence on the
effect of Bbl therapy (hypertension at baseline, blood
pressure levels [<120, 120-140, and >140 mm Hg], in-
study myocardial infarction, AVR, or AS severity); (2) use of
multivariable Cox regression; (3) use of an inverse-
probability-weighted Cox model (using 1/propensity for Bbl
therapy), (4) inclusion of the time-varying effects of AVR
with and without CABG as separate effects in the propensity
score–matched Cox model; and (5) adjustment of the
propensity-matched Cox model with time-updated blood
pressure (last prior to end point or censoring) to evaluate if
Bbl-induced blood pressure lowering explained the observed
survival beneﬁt.
A 2-tailed P<0.05 was regarded as statistically signiﬁcant.
Results
Baseline Characteristics
Among 1873 patients included in the SEAS study, 932 (49.8%)
patients received Bbl at baseline. Hypertension was by far the
main indication (56%) for Bbl therapy, and metoprolol was the
most frequently used Bbl (see Tables S2 and S3 for details).
Bbl therapy was associated with higher age, systolic and
diastolic blood pressure, body mass index, high-density
lipoprotein, triglyceride, glucose, peak aortic velocity, LV
mass, and left atrial diastolic and systolic volume. In addition,
Bbl therapy was associated with a higher prevalence of
hypertension at baseline and with use of digoxin, platelet
inhibitors, Ca2+-blockers, angiotensin-converting enzyme inhi-
bitors and angiotensin receptor blockers, and diuretics, and
with previous atrial ﬁbrillation (Table 1). The propensity-
matched subset was well balanced on all examined baseline
variables (Table 1).
Echocardiographic Variables, Heart Rate, and
Blood Pressure in Patients Treated With Bbl
From ﬁrst to last available in-study value, Bbl-treated patients
showed a 2% larger decrease in systolic blood pressure
(Figure 1, P=0.006) and a 2% greater reduction in LV ejection
fraction (P=0.04). Change values of LV mass, aortic valve area
index, aortic peak jet velocity, and heart rate did not differ
between patients receiving and those not receiving Bbl
therapy at baseline (all P>0.38).
Association of b-Blockade With Outcomes
During a median follow-up of 4.30.9 years, 205 died (102
[11%]) in the Bbl group versus 103 [11%] in the control group);
of those, 101 suffered cardiovascular deaths (52 [6%]) in the
Bbl group versus 49 [5%] without Bbl) (Table 2), and 40 died of
sudden cardiac death (15 [2%] in the Bbl group versus 25 [3%]
without Bbl).
Bbl was associated with lower risk of all-cause and
cardiovascular mortality in inverse-probability-weighted and
propensity-matched analyses (Table 3 and Figure 2), as well
as sudden cardiac death (Table 3). There was no detectable
difference according to Bbl therapy on the risk of myocardial
infarction, stroke, or heart failure before AVR or percutaneous
coronary intervention in propensity-matched analyses
(Table 3). Conversely, Bbl was associated with increased risk
of major adverse cardiovascular events, largely driven by a
doubling in the use of AVR with and without concomitant
CABG (Table 3).
Competing risk analyses with all-cause mortality as a
competing event on the propensity-matched subset conﬁrmed
the results from the cause-speciﬁc Cox models (Table 3). To
test whether Bbl associations with mortality were dependent
on hypertension at baseline, in-study myocardial infarction,
AVR, or AS severity, interaction analyses were performed in
propensity-matched Cox models with all-cause mortality as
the end point. This showed no interaction of Bbl treatment
and risk of all-cause mortality between patients with and
those without previous hypertension (P=0.244), blood pres-
sure levels (P=0.3), in-study myocardial infarction (P=0.825),
in-study AVR (P=0.926), or baseline peak aortic jet velocity
(P=0.140).
Finally, to test whether Bbl treatment outcome was
explained by effects on blood pressure or a higher propensity
for AVR and concomitant CABG among patients receiving Blb
therapy, additional analyses of the propensity-matched Cox
models found that Bbl remained signiﬁcantly associated with
all-cause mortality after adjustment for in-treatment systolic
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blood pressure (hazard ratio 0.52, 95% conﬁdence interval
0.43-0.62, P<0.001) and time-varying AVR with and without
concomitant CABG (hazard ratio 0.54, 95% conﬁdence interval
0.45-0.65, P<0.001).
Discussion
This is the ﬁrst study with a sufﬁcient sample size to evaluate
the association of Bbl therapy with cardiovascular end points
in asymptomatic mild to moderate AS. The primary ﬁnding
was that in propensity-matched analyses and inverse-prob-
ability adjustment, Bbl therapy was not associated with worse
outcome but instead with lower rates of all-cause and
cardiovascular death as well as sudden cardiac death.
Furthermore, Bbl treatment was not associated with an
increased incidence of heart failure before AVR. These
ﬁndings were conﬁrmed in competing risk analyses with all-
cause mortality as a competing event. Thus, this study
supports the notion that Bbls are a safe antihypertensive
treatment option in patients with asymptomatic mild to
moderate AS and preserved LV ejection fraction.
Of note, Bbl was associated with higher rates of major
cardiovascular events, almost exclusively driven by a doubling
in the use of AVR. This could potentially be driven by reverse
causation with Bbl being prescribed to frail patients with
higher systolic blood pressure and a more critical condition
Table 1. Baseline Characteristics According to b-Blocker Therapy
Variable
Total Population (n = 1873) Propensity-Matched (n = 1030)
No b-Blockade (n=941) +b-Blockade (n=932) P Value No b-Blockade (n=515) +b-Blockade (n=515) P Value
Clinical parameters
Age, y 66.59.9 68.69.1 <0.001 67.99.4 67.79.4 0.83
Men, n (%) 594 (63%) 556 (60%) 0.12 319 (62%) 298 (57%) 0.18
Resting heart rate, min1 64.910.0 65.010.6 0.70 66.010.5 65.010.4 0.10
Systolic blood pressure, mm Hg 142.219.0 147.521.0 <0.001 145.819.1 144.920.6 0.49
Diastolic blood pressure, mm Hg 81.29.7 82.910.7 <0.001 82.39.9 82.110.9 0.74
Baseline hypertension, n (%) 358 (38%) 607 (65%) <0.001 292 (57%) 282 (55%) 0.53
Body mass index, kg/m² 26.44.2 27.44.4 <0.001 26.84.5 27.14.4 0.38
Prior atrial fibrillation, n (%) 42 (4%) 135 (14%) <0.001 41 (8%) 45 (9%) 0.65
Peak aortic jet velocity, m/s 3.00.5 3.10.5 <0.001 3.10.5 3.10.5 0.99
Left ventricular ejection fraction, % 65.77.0 65.87.5 0.92 65.57.0 66.27.7 0.19
Left ventricular mass index, g/m² 96.726.2 101.827.8 <0.001 100.127.3 99.626.7 0.78
Left atrial diastolic volume, mL 32 (24-38) 35 (27-42) <0.001 33 (24-38) 34 (25-40) 0.10
Left atrial systolic volume, mL 65 (52-71) 67 (59-78) <0.001 65 (54-71) 67 (56-73) 0.25
Biochemistry
Creatinine 92.614.7 94.215.5 0.03 93.615.5 93.715.7 0.89
eGFR, mL/min per 1.73 m² 68.312.3 67.412.4 0.25 68.312.3 67.412.4 0.25
Glucose, mmol/mL 5.20.7 5.40.8 <0.001 5.30.8 5.30.7 0.92
High-density lipoprotein, mmol/L 1.530.44 1.450.41 <0.001 1.490.43 1.480.42 0.79
Low-density lipoprotein, mmol/L 3.610.92 3.590.91 0.66 3.610.94 3.650.93 0.54
Apolipoprotein B, mmol/L 1.300.26 1.310.27 0.35 1.310.26 1.310.26 0.84
Triglycerides, mmol/L 1.16 (0.90-1.63) 1.29 (1.00-1.83) <0.001 1.20 (0.92-1.71) 1.25 (0.97-1.80) 0.06
Medicine
Digoxin, n (%) 9 (1%) 41 (4%) <0.001 9 (2%) 16 (3%) 0.16
Platelet inhibitor, n (%)* 324 (34%) 530 (57%) <0.001 252 (49%) 242 (47%) 0.53
Ca2+-blocker, n (%) 172 (18%) 331 (36%) <0.001 170 (33%) 155 (30%) 0.31
Renin-angiotensin system inhibitor, n (%) 301 (32%) 469 (50%) <0.001 223 (43%) 239 (46%) 0.32
Diuretics, n (%) 277 (29%) 569 (61%) <0.001 239 (46%) 230 (46%) 1.00
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such as mildly impaired LV function, atrial ﬁbrillation, and/or
subclinical ischemic heart disease. Unfortunately, CT or
coronary angiograms were not available to examine the latter
assumption further. Another mediating factor could be a
possible Bbl-induced functional impairment, which could be
misclassiﬁed as a symptom of AS progression to elicit earlier
AVR.13
To compare our ﬁndings to previous literature, there are few
studies of Bbl therapy in AS patients. In a study of 453 patients
with nonsurgically managed severe AS, Varadarajan et al
showed that among the patients not undergoing AVR, Bbl was
not associated with a survival beneﬁt.4 Although the present
study was comprised of patients with asymptomatic AS, we
found no interaction of Bbl treatment with either AS severity or
time-varying AVR per se and risk of all-cause mortality.
There are several possible explanations for potential
beneﬁts of Bbl therapy in AS patients. First, among older
patients with AS, hypertension is common, found in up to 78%
of patients.7 Hypertension signiﬁcantly modulates LV mass
and geometry14 and is a well-known predictor of increased
cardiovascular morbidity and mortality in both the general and
AS populations.15,16 In hypertension, Bbl is known to not only
lower the blood pressure but also regress LV mass and alter
LV geometry, probably due to the decrease in LV load,17
which is associated with better survival in hypertensive
patients.14 However, adjustment for in-treatment systolic
blood pressure did not change the observed lower rate of
mortality, and we did not ﬁnd interaction with hypertension in
the present study. In patients with increased pressure load
due to hypertension, Bbl not only regresses LV dimensions in
patients with LV hypertrophy but also wall stress and a
noninvasive index of myocardial oxygen demand,18 and the
latter was accompanied by lower rates of cardiovascular
death and myocardial infarction. This provides indirect
support for the conclusion that the known reduction of
morbidity and mortality in survivors of myocardial infarction
by Bbl treatment19 could be caused by the reduction of
myocardial oxygen demand due to lower blood pressure, heart
rate, and myocardial inotropic state. Nevertheless, we were
unable to show regression of LV mass in the Bbl-treated
patients in the current study despite a signiﬁcant decrease in
arterial blood pressure. This may not be surprising because
AS, unlike hypertension, is a major component of increased
Figure 1. In-treatment systolic blood pressure and conﬁdence
intervals according to b-blockade.
Table 2. The Proportion of Patients Meeting End Points According to b-Blocker Therapy
End Point
Total Population (n=1873) Propensity-Matched (n=1030)
No b-Blockade
(n=941)
+b Blockade
(n=932) P Value*
No b-Blockade
(n=515)
+b-Blockade
(n=515) P Value*
MCE, n (%) 224 (24%) 464 (50%) <0.001 160 (31%) 223 (43%) <0.001
All-cause mortality, n (%) 103 (11%) 102 (11%) 0.90 74 (14%) 37 (7%) <0.001
Cardiovascular death, n (%) 49 (5%) 52 (6%) 0.65 38 (7%) 14 (3%) <0.001
Sudden cardiac death, n (%) 25 (3%) 15 (2%) 0.11 19 (4%) 4 (1%) 0.004
AVR, n (%) 156 (17%) 389 (42%) <0.001 105 (20%) 194 (38%) <0.001
CABG, n (%) 31 (3%) 138 (15%) <0.001 26 (5%) 58 (11%) <0.001
Nonhemorrhagic stroke, n (%) 20 (2%) 42 (5%) 0.006 16 (3%) 15 (3%) 0.90
Myocardial infarction, n (%) 16 (2%) 36 (4%) 0.007 14 (3%) 22 (4%) 0.21
HF before AVR, n (%) 14 (1%) 34 (4%) 0.005 11 (2%) 10 (2%) 0.74
PCI, n (%) 5 (1%) 20 (2%) 0.005 5 (1%) 9 (2%) 0.31
Unstable angina, n (%) 3 (0%) 10 (1%) 0.07 3 (1%) 3 (1%) 0.97
AVR indicates aortic valve replacement; CABG, coronary artery bypass grafting; HF, heart failure; MCE, major cardiovascular events; PCI, percutaneous coronary intervention.
*P-values reﬂect univariate Cox regression for the individual end points according to b-blocker therapy.
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LV load and stimulus to LV hypertrophy in AS patients not
directly affected by Bbl therapy.
Second, there is evidence that severe valvular disorders
produce humoral and cytokine activation similar to heart
failure, suggesting a potential role for neurohormonal block-
ade with Bbls.20,21 In a study with 14 patients undergoing
transcatheter aortic valve implantation and 14 matched
controls, Dumonteil et al showed that AS patients had
increased sympathetic nervous system activity associated
with a decrease in sympathetic baroreﬂex gain, and that AVR
normalized these parameters. Hence, progression and prog-
nosis of AS could be related to both hemodynamic impair-
ment and sympathoexcitation with additional impairment of
baroreﬂex restraint of sympathetic tone. This autonomic
dysfunction may contribute to high incidences of sudden
death, mortality, and morbidity in AS patients and also be a
target for Bbl therapy.22
Third, hemodynamically signiﬁcant AS results in LV hyper-
trophy and eventually in LV systolic and diastolic dysfunction
and overt clinical heart failure. AS may also predispose to
mitral regurgitation and left atrial enlargement leading to atrial
ﬁbrillation23 and increase the risk of sudden death,24 the most
feared event in the watchful waiting strategy in asymptomatic
AS patients. In the SHIFT (Systolic Heart failure treatment
with the sinoatrial node inhibitor ivabradine Trial),25 ivabradine
was associated with an 18% lower risk of the primary
composite end point of cardiovascular death or hospitalization
for worsening heart failure in patients with heart failure. Our
group previously demonstrated that increased heart rate is
associated with adverse outcomes in patients with asymp-
tomatic AS26; thus, the lower mortality among Bbl-treated
patients in the present study might be due, at least in part, to
Bbl heart rate–reducing properties.
Table 3. Propensity-Adjusted and Propensity-Matched Hazard Ratios for Adverse End Points According to b-Blocker Therapy Use
End Point
Full Data Set (n=1873) Propensity-Matched (n=1030)
Univariate Multivariable IPTW Univariate Competing Risk*
MCE, n (%) 2.5 (2.1-2.9, P<0.001) 2.4 (2.0-2.9, P<0.001) 1.7 (1.4-2.0, P<0.001) 1.5 (1.2-1.8, P<0.001) 1.5 (1.2-1.8, P<0.001)
All-cause mortality,
n (%)
1.0 (0.7-1.3, P=0.90) 0.9 (0.6-1.3, P=57) 0.6 (0.4-0.8, P=0.002) 0.5 (0.3-0.7, P<0.001) NA
Cardiovascular
death, n (%)
1.1 (0.7-1.6, P=0.65) 0.9 (0.5-1.4, P=0.50) 0.6 (0.4-1.0, P=0.03) 0.4 (0.2-0.7, P<0.001) 0.4 (0.2-0.7, P=0.001)
Sudden cardiac
death, n (%)
0.6 (0.3-1.1, P=0.11) 0.6 (0.2-1.3, P=0.21) 0.3 (0.2-0.7, P=0.003) 0.2 (0.1-0.6, P=0.004) 0.2 (0.1-0.6, P=0.004)
AVR, n (%) 2.9 (2.4-3.5, P<0.001) 2.0 (1.6-2.5, P<0.001) 2.1 (1.7-2.5, P<0.001) 2.0 (1.6-2.5, P<0.001) 2.1 (1.6-2.6, P<0.001)
CABG, n (%) 4.7 (3.2-6.9, P<0.001) 4.5 (2.8-7.1, P<0.001) 2.6 (1.7-4.0, P<0.001) 2.2 (1.4-3.5, P<0.001) 2.3 (1.4-3.7, P<0.001)
Nonhemorrhagic
stroke, n (%)
2.1 (1.2-3.6, P=0.006) 2.0 (1.4-4.0, P=0.049) 1.2 (0.6-2.1, P=0.60) 0.9 (0.4-1.8, P=0.90) 0.9 (0.5-1.9, P=0.86)
Myocardial infarction,
n (%)
2.3 (1.3-4.1, P=0.007) 1.9 (0.9-4.0, P=0.11) 1.3 (0.7-2.6, P=0.40) 1.5 (0.8-3.0, P=0.21) 1.6 (0.8-3.1, P=0.17)
HF before AVR,
n (%)
2.4 (1.3-4.5, P=0.005) 3.7 (2.0-6.8, P<0.001) 1.2 (0.6-2.4, P=0.58) 0.9 (0.4-2.0, P=0.74) 0.9 (0.4-2.2, P=0.84)
PCI, n (%) 4.0 (1.5-10.7, P=0.005) 5.3 (1.5-18.6, P=0.009) 2.0 (0.7-5.7, P=0.21) 1.8 (0.6-5.2, P=0.31) 1.8 (0.6-5.4, P=0.29)
Unstable angina,
n (%)
3.3 (0.9-12.1, P=0.07) 3.73 (0.78-17.84, P=0.10 1.5 (0.4-6.2, P=0.55) 1.0 (0.2-4.8, P=0.97) 1.0 (0.2-5.0, P=0.99)
AVR indicates aortic valve replacement; CABG, coronary artery bypass grafting; HF, heart failure; IPTW, inverse probability of treatment–weighted Cox regression analysis; MCE, major
cardiovascular events; NA, not applicable (patients are matched as shown in Table 1); PCI, percutaneous coronary intervention.
*Fine and Gray estimates of the subdistribution of risk using all-cause mortality as a competing event.
Figure 2. Kaplan-Meier plot for all-cause mortality in the
propensity-matched subset.
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Finally, Bbl therapy has been a cornerstone secondary
prevention therapy for patients with myocardial infarction
since large randomized controlled trials conducted in the
1970s and 1980s demonstrated substantial reductions in
mortality, mostly driven by sudden cardiac death.27 It
therefore is possible that even though SEAS patients were
free from overt coronary disease, Bbl may have prevented
clinical events due to unrecognized concomitant coronary
atherosclerosis.
Data on cardiovascular outcome using different antihyper-
tensive drug regimens in patients with AS are scarce; we have
previously reported from the SEAS data set that treatment
with angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers was not associated with increase or
improvement in all-cause or cardiovascular mortality as well
as sudden cardiac death even though treatment with this drug
class did reduce blood pressure and LV hypertrophy.28 Our
previous report on angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers and our current study on
Bbl are in sharp contrast to our preliminary report on
antihypertensive treatment with diuretics, suggesting
increased all-cause and cardiovascular mortality in patients
with asymptomatic AS.29 Thus, the present study refutes the
concept that Bbl treatment of hypertension is hazardous in AS
patients and supports current clinical practice to use Bbls
when needed in AS patients. However, randomized controlled
studies are missing on other antihypertensive drugs in head-
to-head comparison with Bbl.
Limitations
Our study is a post hoc analysis of a randomized controlled
trial rather than a prespeciﬁed trial of Bbl effects. The
preventive association of Bbl on mortality could possibly be
explained by Bbl patients using other antihypertensive drugs,
calcium channel blockers, statins, aspirin, and other medical
treatment. However, other medical treatments were included
in analyses, and our propensity-matched data set was shown
to be well balanced with regard to all concomitant therapies.
Nevertheless, there are still covariates that are difﬁcult to
balance, such as doctor preferences. In addition, there is a
risk of unmeasured confounding, such as selection bias with
Bbl being completely avoided in the sickest patients.
However, the SEAS study population included ambulatory
patients with normal LV ejection fraction without overt
atherosclerotic disease. Unfortunately, we could not perform
any meaningful analyses of in-study add-on Bbl treatment
because patients’ characteristics were not ascertained when
patients went on and off Bbl therapy. Finally, because variable
Bbl use was reported by the individual study investigators, it
was not possible to independently control whether patients
were in fact on Bbl therapy.
Conclusions
In this large study of asymptomatic patients with mild to
moderate AS, Bbl therapy, in contrast to clinical concern, was
associated in adjusted analyses with lower rates of cardio-
vascular and all-cause mortality as well as sudden cardiac
death in propensity-matched analyses. Thus, use of Bbl as
antihypertensive therapy is safe in patients with asymp-
tomatic AS.
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SUPPLEMENTAL MATERIAL 
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Data S1.  
Predictors used for building propensity score for beta-blocker therapy. 
Age, sex, baseline systolic and diastolic blood pressure, baseline hypertension, prior mitral valve 
incompetence, prior atrial fibrillation, prior supraventricular tachycardia, prior arrhythmia, prior 
palpitations, prior sinus bradycardia, prior angina pectoris, prior left bundle branch block, prior 
ventricular hypertrophy, baseline left atrial systolic and diastolic volume, baseline left ventricular 
end-diastolic volume, left ventricular internal diastolic diameter, systolic posterior wall 
thickness, baseline aortic peak velocity, stress-corrected mid wall shortening, left ventricular 
outflow-tract mean velocity, PQ-interval, QTc-interval, baseline universal ST-segment 
depression, baseline medical treatment including: angiotensin converting enzyme-inhibitor, 
diuretics, calcium antagonist, angiotensin receptor blocker, aspirin or other platelet inhibitor; 
baseline biochemistry including baseline fasting plasma remnant-like particle cholesterol, 
hematocrit, creatinine, alkaline phosphatase, creatinine phosphokinase, high density lipoprotein, 
sodium, total bilirubin, white blood cells, high sensitivity C-reactive protein, chloride, thyroid-
stimulating hormone, glucose, aspartate aminotransferase. 
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Table S1. Most important predictors of beta-blocker therapy: ranked by standardized 
coefficients. 
Analysis of Maximum Likelihood Estimates 
Parameter 
chi-
square 
p-
value 
Standardized 
coefficients* 
Baseline hypertension 69.6269 <.0001 -0.3006 
Concomitant ASA/other platelet inhibitor 50.7172 <.0001 -0.2754 
Concomitant diuretics 62.9185 <.0001 -0.2392 
Prior atrial fibrillation 35.629 <.0001 -0.1914 
Prior angiotensin receptor blocker 17.7232 <.0001 0.1291 
Prior aspirin or other platelet inhibitor 10.4506 0.0012 0.1243 
Aortic peak velocity (m/s) 15.4572 <.0001 0.1147 
Prior supraventricular tachycardia 8.9624 0.0028 -0.0936 
High density lipoprotein 9.2468 0.0024 -0.0902 
Prior Arrhythmia 6.5118 0.0107 -0.0827 
Systolic blood pressure (mmHg) 5.6171 0.0178 0.0725 
Prior ACE inhibitor 4.6823 0.0305 0.0692 
Baseline glucose (mmol/l) 4.693 0.0303 0.064 
Standardized coefficients are coefficients adjusted so that that may be interpreted as having the same, 
standardized scale and the magnitude of the coefficients can be directly compared (ranked). The greater 
the absolute value of the standardized coefficient, the greater the predicted change in the probability of 
the outcome given a standardized change in the corresponding predictor variable, holding constant the 
other predictors in the model. 
Abbreviations – ASA: acetylsalicylic acid, ACE: Angiotensin converting enzyme. 
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Table S2. Indications of beta-blocker treatment. 
Indication % 
Hypertension 55.8 
Atrial fibrillation 17.5 
Arrhythmia* or palpitations  9.8 
Angina  3.4 
Aortic stenosis  1.5 
Heart Failure 1.5 
Tremor 1.2 
Acute myocardial infarction 1 
Atherosclerosis 0.7 
Migraine 0.7 
Aorta aneurism 0.3 
Aortic valve replacement 0.3 
Dyspnea 0.2 
Other/unspecified 7.6 
* Including sick sinus syndrome, sinus tachycardia, ventricular extrasystoles, ventricular tachycardia and 
unspecified tachycardia.   
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Table S3. Beta-blocker types. 
Indication % 
Metoprolol 48 
Bisoprolol 19 
Atenolol 16 
Sotalol 6 
Carvedilol 5 
Propranolol 3 
Nebivolol 1 
Pindolol <1 
Celiprolol <1 
Talinolol <1 
Betaxolol <1 
Acebutolol <1 
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